A Phase III Randomized, Double-Blinded, Placebo-Controlled Rrial to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an ART Including TMC114/RTV and an Investigator-Selected OBR in HIV-1 Infected Subjects with Limit to No Treatment Options. Tibotec (TMC125-C206) 2006-present
A Phase 2, Randomized Study of the Treatment of Antiretroviral Treatment-Experienced, HIV-1 Infected Subjects Comparing Ritonavir-Boosted GS-9137 (GS-9137/r) Versus a Comparator Ritonavir-Boosted Protease Inhibitor (CPI/r) in Combination with a Background Antiretroviral Therapy. Gilead (GS-US-183-0105) 2006-present
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination with Optimized Backgroup Therapy Versus Optimized Background Therapy Along for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects. Agouron/Pfizer (A4001027) 2006-present
A randomized, controlled, partially blinded Phase IIb dose-finding trial of TMC125, in HIV-1 infected subjects with documented genotypic evidence of resistance to currently available NNRTIs and with at least three primary PI mutations. Tibotec – TMC125-C217, 2007-present
Tibotec (TMC125-C223) 2006-present
A Rendomized, Controlled, Parially Blinded Phase IIb Dose-Finding Trial of TMC125, in HIV-1 Infected Subjects with Documented Genotypic Evidence of Resistance to Currently Available NNRTIs and With at Least Three Primary PI Mutations.
A Phase II, Randomized, Blinded, 12-Week Comparison of Elvucitabine in Combination with Efavirenz and Tenofovir Versus Lamivudine in Combination with Efavirenz and Tenofovir in HIV-1 Infected, Treatment-Naïve Subjects with a 12-Week Extension Treatment Period. Achillion (ACH443-015) 2006-present
A Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy. SMART CPCRA. 2006-present.
A Randomized, Controlled, Open-Label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/Ritonavir Versus Lopinavir/Ritonavir in Treatment-Naive HIV-1 Infected Subjects. This trial will be referred to as ARTEMIS. Tibotec (TMC114-C211) 2006-present
A Phase IIb, Randomized, Partially Blinded, Dose-Finding Trial of TM278 in Antiretroviral Naive HIV-1 Infected Subjects. Tibotec (TMC278-C204) 2006-present
An Open-Label Trial with TMC125 in HIV-1 Infected Subjects Who Were Randomized to a TMC125 Treatment Arm in a Sponsor-Selected TMC125 Trial and Were Treated for at Least 48 Weeks. Tibotec (TMC125-C229) 2006-present
A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of Epzicom Versus Truvada Administered in Combination with Kaletra in Antiretroviral-naive HIV-1 Infected Subjects. HEAT. GlaxoSmithKline (EPZ104057) 2006-present
A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908/Ritonavir Given with Abacavir/Lamivudine Fixed Dose Combination. GlaxoSmithKline (COL100758) 2006-present
A Probe Study to Evaluate the Safety, Tolerability, and Immunogenicity of the MRK Adenovirus Serotype 5 Vector (MRKAd5) Human Immunodeficiency Virus Type I (HIV-1) gag Vaccine in HIV-1 Infected Individuals. Merck (V520-014) 2006-present
A Randomized, Controlled, Open-Tiral to Compare the Efficacy, Safety and Tolerability of TMC114/RTV versus LPV/RTV in Treatment-Experiences HIV-1 Infected Subjects. Tibotec (TMC114-C214) 2006-present